Fibroblast Plasma Pen: A Non-Surgical Solution for Skin Tightening
This blog will guide you through everything you need to know about the Fibroblast Plasma Pen—what it is, how it works, who it's for, its benefits, potential side effects, and what to expect during and after treatment.
The Fibroblast Plasma Pen is a non-invasive skin tightening device used in aesthetic medicine to treat signs of aging and skin laxity. It works by delivering controlled plasma energy (ionized gas) to targeted areas of the skin, creating micro-trauma that stimulates fibroblast activity.
Fibroblasts are collagen-producing cells in the dermis responsible for skin firmness and elasticity. When activated through plasma therapy, they accelerate tissue regeneration, resulting in smoother, tighter, and more youthful-looking skin.
The device is FDA-approved in many regions and widely used by trained estheticians and medical professionals.
The treatment works through a process called Plasma Fibroblast Therapy. Here's how it functions: The pen creates a small, controlled arc of plasma (ionized gas) between its tip and the skin's surface. This arc causes tiny micro-injuries (also known as carbon crusts or dots) on the skin. These micro-injuries trigger the body's natural healing response, stimulating fibroblasts to produce collagen, elastin, and new skin cells. Over the following weeks, this cellular activity leads to tighter, firmer, and rejuvenated skin.
Importantly, the pen never touches the skin—the energy discharge occurs just above it, minimizing the risk of deeper tissue damage.
This versatile device can be used on a wide range of facial and body areas, including: Upper and lower eyelids (non-surgical blepharoplasty)
Forehead lines and frown lines
Crow's feet
Nasolabial folds (smile lines)
Neck and décolletage
Jawline tightening
Acne scars
Stretch marks
Sunspots and age spots
Loose stomach skin (postpartum or post-weight loss)
There are several reasons why patients and skincare professionals are choosing the Fibroblast Plasma Pen over traditional surgical options:
No cutting, no stitches, and no general anesthesia are required. It's ideal for those who want significant results without the risks and cost of surgery.
Since the treatment works by stimulating your body's natural collagen production, the results appear gradually and look subtle and natural.
Most patients experience mild swelling and scabbing that resolves in about 7–10 days, significantly less than surgical recovery times.
Depending on skin condition and lifestyle, results can last between 2 to 3 years. Maintenance treatments can extend the benefits.
The pen can treat everything from small fine lines around the eyes to larger areas of sagging skin on the body.
You may be a good candidate if you: They are generally in good health
Have mild to moderate skin laxity or wrinkles
They are not prone to keloid scarring
Are not pregnant or breastfeeding
Have realistic expectations about non-surgical results
Note for darker skin tones: Plasma Pen may carry a higher risk of hyperpigmentation or hypopigmentation for Fitzpatrick skin types IV–VI. A patch test or alternative treatment may be recommended.
A trained provider will assess your skin, medical history, and treatment goals to determine if Plasma Pen is appropriate.
A topical numbing cream is applied and left on for about 30–45 minutes to minimize discomfort during the procedure.
The practitioner applies the Plasma Pen to the skin, creating a series of tiny brown 'carbon crust' dots. Treatment time varies but typically takes 30–90 minutes, depending on the area.
You'll receive detailed aftercare instructions. Swelling and redness are normal for the first 1–3 days, followed by scab formation that naturally falls off within a week.
Proper aftercare is crucial for optimal results and preventing complications: Do not pick or scratch the carbon crusts; allow them to fall off naturally.
the carbon crusts; allow them to fall off naturally. Keep the area clean and dry for the first 24 hours.
for the first 24 hours. Avoid direct sun exposure for at least 2 weeks; wear SPF 50+ daily.
for at least 2 weeks; wear SPF 50+ daily. Use only recommended soothing creams and avoid makeup until healed.
and avoid makeup until healed. Avoid vigorous exercise, saunas, and swimming for at least a week.
While Fibroblast Plasma Pen is considered safe when performed by a trained professional, some potential side effects include: Swelling and redness
Itching or tenderness
Temporary pigmentation changes
Infection (rare, with improper aftercare)
Scarring (very rare, usually if crusts are picked off)
Always choose a qualified provider to minimize risks.
You may notice some tightening immediately after treatment, but full results develop over 6–12 weeks as collagen production continues. For some conditions, such as deeper wrinkles or significant skin laxity, a second or third session may be recommended. Treatment Invasiveness Downtime Results Duration Target Concerns Fibroblast Plasma Pen Non-invasive 7–10 days 2–3 years Wrinkles, sagging, eyelid lift Microneedling Non-invasive 2–3 days 6–12 months Texture, scarring Botox Non-invasive Minimal 3–6 months Expression lines Surgical Facelift Invasive 3–4 weeks 5–10 years Severe sagging, jowls
If you're looking for a non-surgical, effective, and safe way to rejuvenate your skin, the Fibroblast Plasma Pen could be the solution. It provides visible improvements in skin texture, tone, and tightness with minimal risk and downtime.
Whether you're aiming to lift droopy eyelids, reduce fine lines, or refresh your skin without surgery, Plasma Pen treatment offers impressive results backed by science and loved by clients worldwide.
Book your consultation today and take the first step toward smoother, tighter, more radiant skin—naturally and non-invasively.
TIME BUSINESS NEWS
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Single Pass Inc. Launches Global Post-Market Evaluation of the Biopsy Tract Closure Device
LAKE FOREST, Calif.--(BUSINESS WIRE)--Single Pass Inc., a medical technology innovator focused on improving procedural safety in biopsy care, today announced the launch and first enrollment in B-S.A.F.E. (Biopsy with SinglePass: Assessing Fast & Effective Tract Closure) – a global, post-FDA market evaluation to generate real-world evidence of the SinglePass™ electrocautery biopsy closure device. I use SinglePass on every visceral biopsy for both tumor and parenchyma, including kidney and liver! This innovative device efficiently seals biopsy channels, reducing bleeding risks and improving patient safety across all my biopsy procedures. Share Despite the millions of solid organ percutaneous biopsies performed successfully each year, unintended bleeding post-procedure is a real risk requiring additional procedures, longer hospital stays, and increased costs. And in rare instances, the complications can be devastating. The SinglePass device is designed to cauterize the biopsy tract immediately after tissue extraction, offering a novel approach to reduce bleeding complications, enhance procedural efficiency, and optimize patient observation time. 'Single Pass's global post-market evaluation - B-S.A.F.E. - reflects our commitment to innovation backed by evidence,' said John Zehren, CEO of Single Pass Inc. 'We're honored to work alongside frontline clinicians to validate real-world safety, usability, and performance, bringing an innovative solution for patients undergoing biopsy procedures.' B-S.A.F.E. is a multicenter post-market device evaluation that will assess reduction in post-biopsy bleeding and complications, post-biopsy observation time and workflow optimization. 'The SinglePass device represents a transformational advancement in the world of core needle biopsy,' said Dr. Alexander Misono, MD, MBA, RPVI, Chief of Interventional Radiology at Hoag Hospital Irvine in Irvine, CA. 'With the ability of SinglePass to provide immediate and reliable tract closure, we are already witnessing an inevitable shift in the way we manage bleeding risk and patient recovery. I'm proud to contribute to this evaluation and help drive the future standard of care.' "I use SinglePass on every visceral biopsy for both tumor and parenchyma, including kidney and liver!' remarked Dr. Francis Kang, Clinical Chief of Interventional Radiology at Robert Wood Johnson University Hospital in New Brunswick, NJ. 'This innovative device efficiently seals biopsy channels, significantly reducing bleeding risks and improving patient safety across all my biopsy procedures." For more information, visit About Single Pass Inc. Single Pass Inc. is a privately held medical device company dedicated to enhancing safety and workflow efficiency in image-guided biopsy procedures. Its flagship device, the SinglePass Electrocautery Biopsy Closure Device, enables clinicians to cauterize the biopsy tract in a single step, potentially improving patient outcomes and reducing procedural complexity. The company is headquartered in Lake Forest, California.
Newsweek
3 hours ago
- Newsweek
Blueberry Recall Update as FDA Issues Most Severe Risk Level
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A recall of hundreds of boxes of blueberries due to possible contamination with Listeria monocytogenes has now been issued the highest risk warning by the U.S. Food and Drug Administration (FDA). Alma Pak International LLC, based in Georgia, issued a voluntary recall for 400 boxes of its organic blueberries on June 9. The FDA subsequently issued its Class 1 risk classification on July 1. Newsweek contacted Alma Pak International LLC for comment by email outside of regular working hours. Stock image. Alma Pak International LLC issued a voluntary recall for 400 boxes of its organic blueberries on June 9. Stock image. Alma Pak International LLC issued a voluntary recall for 400 boxes of its organic blueberries on June 9. Sina Schuldt/picture-alliance/dpa/AP Images Why It Matters A Class I risk classification represents "a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death," according to the FDA. Listeria infection, or listeriosis, may lead to a range of symptoms in infected individuals. For those experiencing less severe infections, symptoms include fever, muscle aches, nausea, vomiting and diarrhea, which often last between one and three days, the FDA said. For more severe and potentially life-threatening infections, symptoms may include headaches, stiff neck, confusion, loss of balance and convulsions. Severe infections are particularly dangerous for newborns, adults over age 65 and those with weakened immune systems. What To Know A total of 400 boxes of the firm's organic blueberries are impacted by the recall. Each box weighs 30 lbs. The blueberries were shipped to one customer in North Carolina, and can be identified by the Lot numbers: 13325 G1060 / 13325 G 1096. The recall was initiated after the firm obtained positive test results for Listeria monocytogenes during routine testing of the product. What People Are Saying Haley F. Oliver, a professor of food science at Purdue University, told Newsweek previously: "Listeria monocytogenes is a common microorganism that can be found in the natural environment, for example in soil. There are many factors that determine if someone gets listeriosis — a listeria infection. In most instances, an immunocompromised person, so young, old, pregnant or otherwise immunocompromised, must eat contaminated food. The number of bacteria resulting in infection and the amount of time before illness varies considerably. Symptoms vary among people but can include fever, flu-like symptoms, headache, stiff neck, confusion and loss of balance." Mary O'Riordan, a professor of microbiology and immunology at the University of Michigan Medical School, told Newsweek previously: "Listeria has an unusual capacity to grow at refrigerated temperatures. Although the bacterium can contaminate many types of food, cheeses or deli meats that are kept in cold storage for long periods in stores or at home, are a place where listeria can keep growing. "Early symptoms of listeria infection look similar to other common foodborne infections, including fever, diarrhea and vomiting, so it's often not diagnosed right away. Unfortunately, sometimes listeria can spread into the brain and cause more serious illness, like meningitis. In those cases, if people experience headache, stiff neck or confusion, they should seek urgent medical attention." The FDA said on its website: "Pregnant women and their unborn or newborn baby, adults over the age of 65, and those with weakened immune systems, are all considered to be high-risk groups that are susceptible to the serious and adverse effects of listeriosis." What Happens Next The recall is listed as ongoing, according to the FDA. The agency advises anyone who suspects that they have developed symptoms resembling a listeriosis infection to contact their healthcare provider immediately.
The Onion
3 hours ago
- The Onion
FDA Recalls 3 Oranges To Prove They Can Juggle
SILVER SPRING, MD—Issuing a public warning for Americans to watch or they might miss out, the U.S. Food and Drug Administration reportedly recalled three navel oranges Wednesday to prove that they could juggle. 'Toss 'em here,' said spokesperson John Lavietes, adding that American consumers who had recently purchased navel, Valencia, or blood oranges should not consume the citrus fruits but instead bring three of them to the nearest FDA office so the federal agency could show them something. 'It's been a while, but we can definitely do it. Organic, GMO, even a mandarin or tangelo should be brought to this lectern immediately. Come on, any region or distributor works. They have to be firm, though. If they're not firm, we can't do it.' At press time, the FDA had recalled one more orange to replace the one that had rolled under the table.
